Articles By Gail Dutton

  1. What The 2018 Tax Reform Law Means For Life Sciences 4/6/2018

    Tax reform means more cash on hand, but major changes for R&D expensing, net operating losses, and executive compensation.

  2. Crowdfunding Fizzles As VC Soars 3/7/2018

    When the economy crashed a few years ago, crowdfunding offered startups a possible lifeline. But it arrived too late to be much use. Now that money is flooding back into biotech, companies needn’t clutter cap sheets with scores of non-accredited investors, so equity crowdfunding is nearly a nonstarter.

  3. Pharma Cybersecurity After NotPetya 3/7/2018

    Not much has changed in pharma cybersecurity since the NotPeyta ransomware attacked Merck last summer. Many biotech execs think they are too small to be targeted. They’re wrong.

  4. The Missed Opportunity Of Medical Affairs 2/7/2018

    If you’re not using medical affairs strategically, you’re missing an important opportunity. As the voice of science, these specialists are more than just a support function.

  5. 2018 Likely A Banner Year For IPOs 2/7/2018

    2018 will be a good year for IPOs and for financing. Rounds are larger and non-traditional investors are turning to life sciences.

  6. Don't Have A Chief Innovation Officer? Get One … Now 11/8/2017

    Chief innovation officers (CInOs) are poised to become one of the more important executives in the C-suite in pharma just as they are in other industries.

  7. Whistleblower Best Practices 9/8/2017

    At some point in the life of a pharmaceutical company, a whistleblower is likely to come forward with allegations of wrongdoing. The intricacies of marketing alone can create a minefield of potential mistakes. Your best defense begins now.

  8. How The FDA Views Natural Language Processing 8/9/2017

    According to speakers at an FDA workshop, natural language processing (NLP) can be a useful way to extract meaningful information from unstructured data, such as text and tables from electronic health records (EHRs), journals, and social media, but it isn’t ready for full-scale use.

  9. Automation Cuts Drug Development To 5 Years 7/7/2017

    Automation’s advances and widespread integration into the scientific workflow can reduce drug R&D time from the usual 15 years to five, according to a study released by Frost & Sullivan. “Robotics already is meeting most relevant needs in drug discovery. Its impact in the coming few years will be remarkable,” says Cecilia Van Cauwenberghe, associate fellow and industry analyst, TechVision at Frost & Sullivan. “Robotics will make pharmaceutical processes significantly more costand time-effective and allow precise, real-time documentation of every task. That, in turn, contributes to process optimization.”

  10. Precompetitive Partnerships Skyrocket 7/7/2017

    The number of precompetitive collaborations among pharmaceutical companies increased nine-fold between 2005 and 2014 when compared against the 1995 to 2005 period. Meanwhile, traditional partnerships merely doubled, according to “Partnering for Progress: How Collaborations are Fueling Biomedical Advances,” a new study by Deloitte and PhRMA.